OUR STORY

Recent advances in DNA sequencing technologies have revolutionized our ability to discover and analyze specific genetic mutations. While sequencing is sensitive to single nucleotide polymorphisms (SNPs) and smaller genetic variants, current approaches are unable to resolve many of the disease-causing structural variants that may be present across an individual genome. With typical read lengths of 150 bases, short-read DNA sequencing platforms provide a very limited view of these structural changes, even with the application of super-computer-scale bioinformatics analysis. So-called ‘long-read’ technologies only analyze on average a few tens of thousands of bases, which is a tiny fraction of intact human chromosomes that range in size from 47 million to 250 million base pairs. Peer-reviewed publications* continue to cite the need for a technology capable of extracting and analyzing entire chromosomes to detect the full spectrum of structural variation and transform our understanding of the role it plays in cellular function, disease susceptibility and disease progression.

At the lab bench, simple tasks such as fragment sizing still require the use of cumbersome techniques such as gel electrophoresis. These methods can require large amounts of input sample and, for larger DNA fragments, require run times of a full day or longer. The ability to rapidly analyze DNA from a small number of cells would remove the need for cell culturing and allow the analysis of unculturable samples, such as needle biopsies and primary cells.

Genturi Co-founders, Prof. J. Michael Ramsey and Dr. Laurent Menard at the University of North Carolina at Chapel Hill, have dedicated the last decade to developing nanofluidic approaches capable of extracting and analyzing millions of DNA molecules, one-by-one. Genturi’s nanofluidic products will soon enable the rapid analysis of DNA molecules from 100 base pairs up to millions of base pairs, all in a single device.

Genturi is funded by a series A investment from Arch Venture Partners, Hatteras Venture Partners, Stillwater LLC, and Eleven Two Capital.

* Chiang et al. The impact of structural variation on human gene expression. Nature Genetics 49, 692-699 (2017).

* Nazarenko et al. Genomic structural variations for cardiovascular and metabolic comorbidity. Scientific Reports 7:41268 (2017).

* Collins et al. Defining the diverse spectrum of inversions, complex structural variation, and chromothripsis in the morbid human genome. Genome Biology 18:36 (2017).

* Chaisson et al. Genetic variation and the de novo assembly of human genomes. Nature Reviews Genetics 16, 627-640 (2015).

TECHNOLOGY AND PRODUCTS

Genturi’s nanofluidic products will have several key advantages over current methods:

  • High capacity and scalability – analyze thousands to millions of individual DNA molecules in as little as 5 minutes

  • Broad range of DNA sizes – detect and quantify DNA ranging in size from 100bp up to millions of base pairs

  • Minimal sample input requirements – perform routine analysis of small numbers of cells

  • Integrated micro and nanofluidics – minimize user operation with intuitive workflow

  • High volume single-use consumables – enable low overall cost per sample

Megabase Genomic DNA Extraction

Real-Time Mapping in Nanofluidic Networks

Single-Point Florescence Detection with Resolution Down to 100 Bases

LEADERSHIP TEAM

Genturi’s leadership team combines an established track record of breakthrough scientific innovation and entrepreneurial success. The team features diverse backgrounds from leading academic institutions and genomics technology companies.

J. Michael Ramsey, PhD
Scientific Founder
and Director
Read Bio

J. Michael Ramsey, PhD
Scientific Founder
and Director
Read Bio

Laurent D. Menard, PhD
Scientific Co-founder and
Director of Microfluidics Research
Read Bio

Laurent D. Menard, PhD
Scientific Co-founder and
Director of Microfluidics Research
Read Bio

Peter Honkanen
Chief Executive Officer
and Director
Read Bio

Peter Honkanen
Chief Executive Officer
and Director
Read Bio

Michael Dial, PhD
Director
Read Bio

Michael Dial, PhD
Director
Read Bio

Keith L. Crandell
Director
Read Bio

Keith L. Crandell
Director
Read Bio

Michael Albin, PhD
Director
Read Bio

Michael Albin, PhD
Director
Read Bio

CAREER OPPORTUNITIES

Genturi is currently actively recruiting top scientific and business talent. Our compensation packages include significant early stage equity, competitive salary, annual bonus, and health benefits. Contact us today to learn more at careers@genturi.com.

Senior/Principal Assay Development Scientist

Senior/Principal Assay Development Scientist, Genturi Inc, Woburn, MA, USA

 

Genturi Inc is an early stage genomics technology company based in greater Boston. Genturi is developing a proprietary long DNA molecule analysis technology for research and subsequent clinical applications. Genturi is well-funded by a leading group of biotechnology venture capital investors.

Reporting to the Vice President of Assay Development, the Principal Assay Development Scientist will be responsible for designing and developing novel digital assay content for the Genturi System. This is a high impact opportunity for a creative individual capable of strategizing, innovating, designing, and executing experiments in the research laboratory. This individual will have a significant impact in the creation of Genturi’s organization, products, and culture. The compensation package includes early stage equity, competitive salary, annual bonus, and health benefits.

Specific responsibilities

The Senior/Principal Assay Development Scientist:

  • Conceive and develop novel digital assays for the Genturi platform
  • Work closely with applications and marketing to translate market and customer requirements into assay development goals
  • Work closely with the software/computational team to design and execute experiments to assist in novel algorithm development
  • Perform library construction for RNAseq, WGS, amplicon-seq and additional assays to support product development efforts
  • Engage and liaise with collaborators and key opinion leaders in the genomics space
  • Create and manage project timelines

    · Lead assay migration efforts onto system prototypes

  • Apply statistical rigor to experimental design and data analysis
  • Train and Mentor junior scientists
  • Systematically design and execute assay optimization efforts applying DOE

Experience and qualifications

  • PhD or masters in molecular biology, cell biology, or related discipline and at least 5 years (PhD) or 10 years (MS) of industry experience
  • Extensive experience and understanding of general molecular biology techniques – DNA isolation, PCR, qPCR, electrophoresis.
  • Hands-on experience in NGS library construction and NGS QC.
  • Experience in the development and launch of a commercial product

    · Excellent communication skills and attention to detail.

  • Strong time-management skills and the ability to multi-task
  • Superior critical thinking and problem-solving skills
  • Entrepreneurial spirit and demonstrate flexibility and adaptability in fast-paced work environments.

Ideally, the Senior/Principal Data Algorithm Scientist will have a combination of both small and large company instrumentation development experiences and will understand how to implement software solutions for data analysis and hardware control to early instrumentation prototype development. Send your resume to careers@genturi.com with the job title in the subject line.

Senior/Principal Software Engineer

Senior/Principal Software Engineer, Genturi Inc, Woburn, MA, USA

 

Genturi Inc. is a startup stage genomics technology company based in greater Boston and is developing its long DNA molecule analysis technology for research and subsequent clinical applications. Genturi is well funded by a leading group of biotechnology venture capital investors.

Reporting to the Director of Engineering, the Senior/Principal Software Engineer will be responsible for leading the software development and integration of firmware subsystems for instrument control and working with Algorithm Scientists to implement a data analysis package for single molecule DNA measurement analysis. This is an outstanding opportunity for the right individual to have a significant impact in the creation of Genturi’s organization, products, and culture. The compensation package includes early stage equity, competitive salary, annual bonus, and health benefits.

Specific responsibilities

The Senior/Principal Data Algorithm Scientist:

  • Will work with the Director of Engineering to design and implement a system software architecture to control all components of an automated instrument.
  • Design and develop firmware subsystems for fluorescence measurements.  Includes ownership of software architecture, design, interface, embedded software, and source code.
  • Integrate firmware subsystems and manage high level software dependencies across system.
  • Evaluate and select the appropriate software development tools.
  • Will be responsible for the software development and implementation of an automated data analysis package for analyzing static or streaming data.
  • Will model instrument response to guide future experiments and product development.
  • Will implement real time feedback loops to control hardware during measurement.
  • Define the electronic and firmware subsystem requirements and risks.
  • Identify test strategy and generate test protocols.
  • Will organize and manage data streaming from instrumentation.
  • Engage external consultants, development partners, and collaborators as needed.
  • Works closely with assay and engineering teams to define product performance metrics.
  • Work effectively across multiple technical disciplines in a small team environment.
  • Presents strategy, results, and technical updates to team members.

Experience and qualifications

  • Ideally a MS/PhD degree in a relevant technical discipline such as Computer Science, Electrical, or Mechanical Engineering.
  • 5-10 years’ experience in software/firmware development for instrument automation.
  • Familiarity with .NET/C#/LabVIEW/Java/HTML a plus.
  • In-depth knowledge and experience integrating multiple firmware subsystems into a robust system architecture that includes feedback loops for real time hardware control.
  • Experience with product launch and rolling our software updates to on market systems needed.

Ideally, the Senior/Principal Software Engineer will have a combination of both small and large company instrumentation development experiences and will understand how to apply best hardware design practices to early instrumentation prototype development. Send your resume to careers@genturi.com with the job title in the subject line.

Senior Systems Engineer

Senior Systems Engineer, Genturi Inc, Woburn, MA, USA

 

Genturi Inc is a startup genomics technology company based in greater Boston and is developing its long DNA molecule analysis technology for research and subsequent clinical applications. Genturi is well funded by a leading group of biotechnology venture capital investors. Reporting to the Director of Engineering, the Senior Systems Engineer will play a key role in the design, development, and documentation of a single DNA molecule analysis system. This is an outstanding opportunity for the right individual to have a significant impact in the creation of Genturi’s organization, products, and culture. The compensation package includes early stage equity, competitive salary, annual bonus, and health benefits.

Specific responsibilities

The Senior Systems Engineer:

  • Work as part of a cross functional product development team, perform complex systems development and design work that may include hardware design, software development, model/algorithm formulation, and system architecture analysis and design.
  • Lead the development and maintenance of product and system requirements, detailed specifications, and develop validation plans and the associated documentation.
  • Own product requirements matrix traceability including requirement tracing from top level functional requirements through to test plan cases.
  • Will design and execute experiments to verify performance of the instruments, execute the experiments, and analyze the data including data interpretation and root-causing analysis.
  • Conducts reliability and/or system tests to approved test plans including compliance with external standard and generate functional test plans and reports.
  • Participate in analysis of test data including detailed root cause analysis of failures.
  • Develops and conducts system level characterization tests for product feasibility and development.
  • Engage external consultants, development partners, and collaborators as needed.
  • Presents strategy, results, and technical updates to team members.
  • Highly effective verbal and written communication skills.

Experience and qualifications

  • BS/MS degree in an Engineering discipline such as Mechanical, Electrical, or Systems.
  • Minimum of 10 years’ experience writing functional product requirements and specifications as well as verification test plans in an instrumentation development environment.
  • Technical understanding of system design, electronics, mechanical, and software integration.
  • Experience with designing experiments, data analysis, and interpretation including Design of Experiment approaches and statistical software packages including JMP or Minitab.
  • In-depth knowledge and experience integrating subsystems into a robust system architecture.
  • Experience with the product launch of an instrument a must.
  • Familiarity with MATLAB/Python/.NET/C#/LabVIEW/Java/HTML a plus.
  • Familiarity with SolidWorks/3D-CAD tools a plus

Ideally, the Senior Systems Engineer will have a combination of both small and large company instrumentation development experiences and will understand how to apply best hardware design practices to early instrumentation prototype development. Send your resume to careers@genturi.com with the job title in the subject line.

CONTACT US

Genturi is headquartered in Woburn, MA, a growing biotech and life sciences hub just north of Boston.

8 Cabot Road, Suite 3800

Woburn, MA 01801

Phone: 617-767-2362
Email: info@genturi.com

Genturi

Sign up today to join our growing community and receive email updates on our latest technology developments.

15 + 10 =

J. Michael Ramsey, PhD

Scientific Founder and Director

 

Dr. J. Michael Ramsey is the Scientific Founder and Director at Genturi. He also holds the Minnie N. Goldby Distinguished Professor of Chemistry Chair at the University of North Carolina - Chapel Hill.  In addition, he is a member of the faculty in the Departments of Biomedical Engineering and Applied Physical Sciences, and the Carolina Center for Genome Sciences. His present research interests include microfabricated chemical instrumentation, micro- and nanofluidics, single molecule DNA characterization, single cell assays, point-of-care clinical diagnostic devices, and highly miniaturized mass spectrometry.

Dr. Ramsey is a member of the National Academy of Engineering and a Fellow of the Optical Society of America, the American Chemical Society, and the American Institute for Medical and Biological Engineering. He is a recipient of a senior Alexander von Humboldt Award, the Frederick Capillary Electrophoresis Award, the A. J. P. Martin Gold Medal for Separation Science, the Marcel J.E. Golay Award in Capillary Chromatography, the Jacob Heskel Gabbay Award in Biotechnology and Medicine, the American Chemical Society Division of Analytical Chemistry Award in Chemical Instrumentation, the Pittsburgh Analytical Chemistry Award, the American Chemical Society Award in Chromatography, the CASSS Award for Outstanding Achievement in Separation Science, and the Ralph N. Adams Award in Bioanalytical Chemistry. Moreover, Dr. Ramsey is the sole scientific founder of Caliper Technologies (NASDAQ:CALP), renamed Caliper Life Sciences, and acquired by PerkinElmer in 2011. He is also the scientific founder of privately held 908 Devices Inc., a company developing revolutionary compact mass spectrometry and chemical separations-based products. Prof. Ramsey has published over 300 peer-reviewed papers (H-index = 61) and presented over 500 invited, plenary, or named lectures.  In addition, he has over 100 issued and 20 pending patents.

Laurent D. Menard, PhD

Scientific Co-founder and Director of Microfluidics Research

 

Dr. Laurent Menard is the Scientific Co-founder and Director of Microfluidics Research at Genturi Inc. He has a diverse background in the chemical sciences and has conducted research throughout his career with an underlying theme of innovation through nanotechnology. As a senior research scientist in the laboratory of Prof. J. Michael Ramsey at the University of North Carolina at Chapel Hill, he led a team of chemists and engineers developing nanofluidic platforms for high-throughput, high-resolution mapping of human genomes.

He is an expert in microfabrication and nanofabrication techniques, electron microscopy, surface chemistry, micro- and nanofluidics, and the characterization of biological macromolecules such as DNA using nanofluidic systems. Dr. Menard received a PhD in Analytical Chemistry from the University of Illinois at Urbana-Champaign in 2007, where he was supported through a NDSEG fellowship. He is an author on more than 25 peer reviewed journal articles and conference proceedings, an inventor on six pending and granted patents.

Peter Honkanen

Chief Executive Officer and Director

 

Peter Honkanen is the CEO and Director of Genturi Inc. He has served in leadership positions in the high tech and life science industries for the past 25 years. Prior to joining Genturi, Mr. Honkanen was the founding CEO of Aushon Biosystems, an ultra-sensitive, multiplexed immunoassay company acquired by Quanterix in January 2018. He also led the development and commercialization of numerous life science technologies at Affymetrix, Genetic Microsystems and General Scanning. He holds numerous patents covering the fabrication, processing and analysis of both genomic and proteomic assays.

Mr. Honkanen has an MS in Business Management from the Massachusetts Institute of Technology (MIT) Sloan School of Management and a BS in Electrical Engineering from Boston University. He is a former US Navy officer (Intelligence). He currently serves on the MIT Sloan Americas Executive Board.

Michael Dial, PhD

Director
Principal, Hatteras Venture Partners

 

Prior to joining Hatteras, Mike was a Vice President in Silicon Valley Bank’s Corporate Finance Scientific Founder and Director Scientific Co-founder and Group where he focused on emerging life science companies and venture capital funds. Prior Read Bio Director of Microfluidics Research to SVB, he held research scientist positions in the Department of Biochemistry at UNC-Chapel Hill, the Laboratory of Structural Biology at the National Institute of Environmental Health Sciences, and the UNC-Duke Michael Hooker Proteomics Center. He has performed research in the fields of cell cycle regulation, proteomics, and cancer therapy and holds a Ph.D. in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.

 

Mike is also the Manager of the Carolina Research Ventures Fund, a fund dedicated to UNC-Chapel Hill related start-ups. Mike serves on the boards of Genturi and Stride Therapeutics and is a board observer at Spyryx, Curoverse, and Lysosomal Therapeutics.

Keith L. Crandell

Director
Managing Director and Co-Founder, ARCH Venture Partners

 

Keith Crandell is a Managing Director and Co-Founder of ARCH Venture Partners, L.P., a global seed and early stage venture capital firm focused on innovations in the life and physical sciences. ARCH Venture partners is investing its ninth fund and manages $2.7 billion. Keith holds an M.B.A. from The University of Chicago (Booth), an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.

Michael Albin, PhD

Director

 

Following a Ph.D. in chemistry at Pennsylvania State University and postdoctoral research in biochemistry at the California Institute of Technology, Michael worked at SYVA diagnostics followed by fifteen years at Applied Biosystems Inc rising to the role of VP of Science and Technology, and then VP of Strategic Technologies of the parent company Applera Corp, an S&P 500 company.

As VP of Science and Technology at Applied Biosystems Inc (now Life Technologies Inc.), Michael was responsible for R&D programs with a budget in excess of US$100 million and overseeing the development of the company’s product pipeline via internal development, investment and acquisition.

In recent years, Michael has worked as a private consultant focusing on technical and strategic assessments and the positioning of a wide range of companies in the life sciences, molecular diagnostics, and personalized medicine. In addition, he has been appointed to carry out due diligence for venture capital and other investment organizations worldwide.

J. Michael Ramsey, PhD

Scientific Founder and Director

 

Dr. J. Michael Ramsey is the Scientific Founder and Director at Genturi. He also holds the Minnie N. Goldby Distinguished Professor of Chemistry Chair at the University of North Carolina - Chapel Hill.  In addition, he is a member of the faculty in the Departments of Biomedical Engineering and Applied Physical Sciences, and the Carolina Center for Genome Sciences. His present research interests include microfabricated chemical instrumentation, micro- and nanofluidics, single molecule DNA characterization, single cell assays, point-of-care clinical diagnostic devices, and highly miniaturized mass spectrometry.

Dr. Ramsey is a member of the National Academy of Engineering and a Fellow of the Optical Society of America, the American Chemical Society, and the American Institute for Medical and Biological Engineering. He is a recipient of a senior Alexander von Humboldt Award, the Frederick Capillary Electrophoresis Award, the A. J. P. Martin Gold Medal for Separation Science, the Marcel J.E. Golay Award in Capillary Chromatography, the Jacob Heskel Gabbay Award in Biotechnology and Medicine, the American Chemical Society Division of Analytical Chemistry Award in Chemical Instrumentation, the Pittsburgh Analytical Chemistry Award, the American Chemical Society Award in Chromatography, the CASSS Award for Outstanding Achievement in Separation Science, and the Ralph N. Adams Award in Bioanalytical Chemistry. Moreover, Dr. Ramsey is the sole scientific founder of Caliper Technologies (NASDAQ:CALP), renamed Caliper Life Sciences, and acquired by PerkinElmer in 2011. He is also the scientific founder of privately held 908 Devices Inc., a company developing revolutionary compact mass spectrometry and chemical separations-based products. Prof. Ramsey has published over 300 peer-reviewed papers (H-index = 61) and presented over 500 invited, plenary, or named lectures.  In addition, he has over 100 issued and 20 pending patents.

Laurent D. Menard, PhD

Scientific Co-founder and Director of Microfluidics Research

 

Dr. Laurent Menard is the Scientific Co-founder and Director of Microfluidics Research at Genturi Inc. He has a diverse background in the chemical sciences and has conducted research throughout his career with an underlying theme of innovation through nanotechnology. As a senior research scientist in the laboratory of Prof. J. Michael Ramsey at the University of North Carolina at Chapel Hill, he led a team of chemists and engineers developing nanofluidic platforms for high-throughput, high-resolution mapping of human genomes.

He is an expert in microfabrication and nanofabrication techniques, electron microscopy, surface chemistry, micro- and nanofluidics, and the characterization of biological macromolecules such as DNA using nanofluidic systems. Dr. Menard received a PhD in Analytical Chemistry from the University of Illinois at Urbana-Champaign in 2007, where he was supported through a NDSEG fellowship. He is an author on more than 25 peer reviewed journal articles and conference proceedings, an inventor on six pending and granted patents.

Peter Honkanen

Chief Executive Officer and Director

 

Peter Honkanen is the CEO and Director of Genturi Inc. He has served in leadership positions in the high tech and life science industries for the past 25 years. Prior to joining Genturi, Mr. Honkanen was the founding CEO of Aushon Biosystems, an ultra-sensitive, multiplexed immunoassay company acquired by Quanterix in January 2018. He also led the development and commercialization of numerous life science technologies at Affymetrix, Genetic Microsystems and General Scanning. He holds numerous patents covering the fabrication, processing and analysis of both genomic and proteomic assays.

Mr. Honkanen has an MS in Business Management from the Massachusetts Institute of Technology (MIT) Sloan School of Management and a BS in Electrical Engineering from Boston University. He is a former US Navy officer (Intelligence). He currently serves on the MIT Sloan Americas Executive Board.

Michael Dial, PhD

Director
Principal, Hatteras Venture Partners

 

Prior to joining Hatteras, Mike was a Vice President in Silicon Valley Bank’s Corporate Finance Scientific Founder and Director Scientific Co-founder and Group where he focused on emerging life science companies and venture capital funds. Prior Read Bio Director of Microfluidics Research to SVB, he held research scientist positions in the Department of Biochemistry at UNC-Chapel Hill, the Laboratory of Structural Biology at the National Institute of Environmental Health Sciences, and the UNC-Duke Michael Hooker Proteomics Center. He has performed research in the fields of cell cycle regulation, proteomics, and cancer therapy and holds a Ph.D. in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.

 

Mike is also the Manager of the Carolina Research Ventures Fund, a fund dedicated to UNC-Chapel Hill related start-ups. Mike serves on the boards of Genturi and Stride Therapeutics and is a board observer at Spyryx, Curoverse, and Lysosomal Therapeutics.

Keith L. Crandell

Director
Managing Director and Co-Founder, ARCH Venture Partners

 

Keith Crandell is a Managing Director and Co-Founder of ARCH Venture Partners, L.P., a global seed and early stage venture capital firm focused on innovations in the life and physical sciences. ARCH Venture partners is investing its ninth fund and manages $2.7 billion. Keith holds an M.B.A. from The University of Chicago (Booth), an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.

Michael Albin, PhD

Director

 

Following a Ph.D. in chemistry at Pennsylvania State University and postdoctoral research in biochemistry at the California Institute of Technology, Michael worked at SYVA diagnostics followed by fifteen years at Applied Biosystems Inc rising to the role of VP of Science and Technology, and then VP of Strategic Technologies of the parent company Applera Corp, an S&P 500 company.

As VP of Science and Technology at Applied Biosystems Inc (now Life Technologies Inc.), Michael was responsible for R&D programs with a budget in excess of US$100 million and overseeing the development of the company’s product pipeline via internal development, investment and acquisition.

In recent years, Michael has worked as a private consultant focusing on technical and strategic assessments and the positioning of a wide range of companies in the life sciences, molecular diagnostics, and personalized medicine. In addition, he has been appointed to carry out due diligence for venture capital and other investment organizations worldwide.